Disruptive treatments for acute, inflammatory diseases such as sepsis

Read More

Meet CEO Mikael Lindstam at BioEurope Spring on 18-20 March

Read More

BioStock article: Aptahem comments on the publication in Cells

Read More

Aptamers

Aptamers are synthetic fragments of nucleic acid polymers which lack genetic information. They are the only known alternative to antibodies. Unlike antibodies, aptamers are synthetically produced, without any trace of endotoxin or other biological impurities as well as showing low immunogenicity.

Read More

Apta-1 in clinical phase

Disruptive in-house research showing the aptamer Apta-1’s uniqe multi-mechanistic profile. Apta-1 is currently in clinical phase 1 for the indication sepsis.

Read More

Investor Relations

Sepsis represents the highest healthcare costs of all critical conditions. In USA the yearly cost is estimated to 62 billion USD for the treatment and care of sepsis patients. Today there is no efficient treatment available.

Read More

About Aptahem and sepsis

Aptahem is a biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase with the main indication sepsis and other acute inflammatory conditions. This medical condition affects yearly 50 million people around the world and is lethal for more than 20-25% of these. Aptahem’s goal is to address the global medical need of treatments for sepsis and critical conditions associated with sepsis.

Today there is no treatment for sepsis or septic shock but only supporting treatment to maintain a healthy blood pressure and to improve oxygenation to prevent organ failure.

Video from Global Sepsis Alliance

Read More

Financial Calendar

  • Apr
    5
    2024

    Annual Report 2023

  • May
    15
    2024

    Annual General Meeting 2024

  • May
    31
    2024

    Interim Report Q1 2024

Presentations

Live presentation with CEO Mikael Lindstam (in swedish)

2024-01-24